The transcription factor FOXP3 has been identified as a tumour suppressor in the breast and prostate epithelia, but little is known about its specific mechanism of action. We have identified a feed-forward regulatory loop in which FOXP3 suppresses the expression of the oncogene SATB1.
Introduction
The X-linked gene FOXP3 is a member of the Forkhead/winged helix family of transcription factors, which was first identified in T-regulatory (Treg) cells as essential for formation and function. Treg are a rare subset of T cells responsible for preventing inappropriate immune responses and promoting immune tolerance (Fontenot et al., 2003; Marson et al., 2007; Feuerer et al., 2009; Josefowicz and Rudensky, 2009) . Although originally thought to be T-cell-restricted, FOXP3 expression appears widespread in normal epithelia and aberrant in solid tumours, suggesting that FOXP3 can function as a tumour suppressor (Chen et al., 2008; Martin et al., 2010; Ladoire et al., 2011) . As evidence, female heterozygous, Foxp3-knockout mice have a significant age-dependent increase in spontaneous mammary cancer. Critically, tumour cells, but not adjacent normal breast tissue from these mice, showed skewed X-inactivation, resulting in the exclusive loss of the wild-type Foxp3 allele in the cancer (Zuo et al., 2007b) . Further evidence for a tumour-suppressor role comes from the prostate-specific ablation of FOXP3 by conditional gene targeting, which leads to prostate hyperplasia and precancerous lesions . Evidence for FOXP3 tumour-suppressor function in human epithelial cells is suggested by several studies reporting a high frequency of somatic mutations and deletions of FOXP3 in human breast, ovary and prostate tumour samples (Zuo et al., 2007a, b) . Reintroduction of FOXP3 into breast or prostate cancer cell lines results in growth-inhibitory and proapoptotic effects in vitro and in vivo, confirming this causal link (Zhang et al., 2006; Zuo et al., 2007a; Wang et al., 2009) .
FOXP3 is able to function as a transcriptional repressor or activator in both Treg (Marson et al., 2007; Zheng et al., 2007; Sadlon et al., 2010) and epithelial cells. For example, FOXP3 directly represses the ERBB2 and SKP2 oncogenes while maintaining the expression of the p21 tumour suppressor in the breast epithelium (Zuo et al., 2007a, b; Liu et al., 2009) . In prostate cells, FOXP3 has also been shown to directly repress c-myc transcription , an oncogene frequently overexpressed in many human cancers (Wolfer et al., 2010) . More recently, induction of FOXP3 by p53 following DNA damage in breast epithelial cells has been reported, with increased FOXP3 levels contributing to the growth-suppressive activity of the p53 pathway (Jung et al., 2010) . Together these data suggest that FOXP3 controls key oncogenes and tumour suppressors in epithelial cells, although the mechanisms and pathways have yet to be fully elucidated. This raises the question as to whether FOXP3 is linked to other genes involved in maintaining healthy breast epithelium.
While the targets of FOXP3 in epithelial cells are still largely unknown, genome-wide chromatin immunopre-cipitation (ChIP-on-chip) studies in human and mouse Treg cells have identified a large number of potential FOXP3 target genes, including a number of loci encoding microRNAs (miRs) (Marson et al., 2007; Zheng et al., 2007; Sadlon et al., 2010) . The extent to which FOXP3 regulates common or unique sets of genes in these two different cell types is currently unclear; however, identification of miRs as potential targets for FOXP3 regulation is of interest given their regulatory role in both normal and disease tissue. miRs are a class of small non-coding RNAs that modulate gene expression by binding to the 3 0 -untranslated region (3 0 -UTR) of target genes, resulting in translational repression and increased mRNA degradation (Filipowicz et al., 2008; Bartel, 2009) . In breast cancer, expression profiling has demonstrated clear differences in the expression of specific miRs between normal and primary tumour tissue, including miRs that are both up-and downregulated (Iorio et al., 2005; Volinia et al., 2006) . The mechanisms and consequences of miR deregulation within a cancer cell are still being determined, although it is likely that changes in the levels and the activity of transcriptional regulators and the miR-processing machinery, coupled with alterations in miR copy number, contribute to the overall deregulation of miR expression (Zhang et al., 2006; Selcuklu et al., 2009) . There is now evidence for the participation of miR and transcription factor combinations in feedback and feed-forward loops (Tsang et al., 2007; Brosh et al., 2008; Bartel, 2009; Re et al., 2009) , and such miR/transcription factor feed-forward loops enhance the robustness and responsiveness of the gene regulation network (Filipowicz et al., 2008) .
Special AT-rich Binding Protein-1 (SATB1), an oncogene involved in the promotion of breast tumour growth and metastasis (Han et al., 2008; Li et al., 2010a, b) , is expressed in aggressive primary human epithelial breast tumours and is an independent prognostic factor for breast cancer (Han et al., 2008) . SATB1 is expressed in a number of metastatic breast cancer cell lines but not in non-invasive cell lines (Han et al., 2008) . Furthermore, knockdown of SATB1 in aggressive breast cancer cells significantly inhibited the growth of tumours in both in vitro and in vivo models of metastasis, providing evidence of its role in cancer progression (Han et al., 2008; Richon, 2008) . SATB1 is a DNA-binding protein that functions as a global regulator of transcription through diverse mechanisms. These include maintenance of specific chromatin architecture, such as the creation of chromatin loop domains by selectively tethering specific matrix attachment regions to the nuclear matrix, and recruitment of chromatin-modifying complexes to these anchor points (Yasui et al., 2002; Cai et al., 2003; Galande et al., 2007) .
Here we show that FOXP3 overexpression in the BT549 breast cancer cell line can suppress SATB1 mRNA and protein levels. Specifically we show that FOXP3and FOXP3-induced miRs hsa-miR-7 (miR-7) and hsa-miR-155 (miR-155) form a feed-forward regulatory loop to suppress SATB1. We propose that restoration of this regulation may provide a new approach in the treatment of breast cancer.
Results
Identification of SATB1 as a target for a FOXP3-miR feed-forward regulatory loop In a previous study we performed ChIP-on-chip experiments to identify genes potentially regulated by FOXP3 in human Treg cells . Ingenuity Pathways Analysis of these genes indicates a statistically significant enrichment of genes associated with cancer, apoptosis, control of growth and proliferation (Supplementary Figure S1) . We hypothesized that some of these targets may also be regulated by FOXP3 in the breast epithelium. Furthermore, because a number of miRs were found to be regulated by FOXP3 in human Treg cells , we searched the list of FOXP3 target genes for genes with a known role in cancer, apoptosis and control of growth that were also predicted to be targets of miRs that are regulated by FOXP3. Putative miR-binding sites in the 3 0 -UTRs of candidate FOXP3 target genes were first identified by using the miR target prediction programmes in miRGen (http://www.diana.pcbi.upenn. edu/miRGen.html). Then, using the selection criteria that a candidate binding site must be found by three separate prediction programmes (miRanda, PicTar4 and TargetScan), we identified SATB1 as a gene with multiple FOXP3-binding sites in its promoter region ( Figure 1a ) as well as predicted binding sites for the FOXP3-regulated miR-7 and miR-155 in its 3 0 -UTR (Figure 1b ).
FOXP3 overexpression reduces SATB1 levels in BT549 cells
In order to determine whether FOXP3 levels influence SATB1 expression in breast cancer cells, the lentiviral pLVEIG-FOXP3 vector was used to stably express human FOXP3 in BT549 human breast cancer cells. BT549 cells have been demonstrated to express SATB1, which is associated with their metastatic potential (Han et al., 2008) , and express low/negligible levels of FOXP3 ( Figure 2 ). Multiple independent transductions of BT549 cells with either a FOXP3-containing or a control green fluorescent protein (GFP) lentivirus generated cell lines in which long-term stable expression of the vector was observed (Supplementary Figure S2) . A reduction in the proliferative capacity of the BT549 cell line was observed when FOXP3 was overexpressed (Supplementary Figure S3) , and comparison of the GFP-transduced cells with the parental lines confirmed that this reduction was not due to the effects of lentiviral integration. FOXP3 overexpression in BT549 cells was not associated with significant loss of viability. The impact of FOXP3 expression on SATB1 levels in BT549 cells was then determined by reverse transcription-PCR (RT-PCR) and western blot analysis. SATB1 mRNA levels were reduced by B60% (Po0.0001, n ¼ 3 separate transduction pools) in BT549 cells in which FOXP3 was overexpressed as compared with that in untransduced BT549 cells (Figure 2a ). By contrast, SATB1 mRNA levels were not significantly altered when cells were transduced with a GFP-expressing control vector. Similar reductions in SATB1 levels were Figure S4 ). The effect of FOXP3 on SATB1 protein levels was confirmed by western blotting (Figure 2b ).
Together, these data indicate that FOXP3 repressed SATB1 levels in breast cancer cell lines.
FOXP3 regulates SATB1 transcription in BT549 cells
FOXP3 chromatin immunoprecipitation arrays (ChIPon-chip) in Treg cells indicated several potential binding interactions in the SATB1 locus ( Figure 1a ). To test whether FOXP3 directly represses the SATB1 promoter in breast cancer cells, we constructed SATB1-promoter luciferase reporter constructs. These were transfected into control BT549 cells or BT549 cells expressing FOXP3. We examined the FOXP3-dependent regulation of two binding regions (BR-1 and BR-2) located À3 kb and þ 0.5 kb upstream and downstream from the SATB1 transcription start site respectively. BT549 cells transfected with a SATB1 promoter reporter containing either FOXP3 BR-1 or BR-2 showed significant repression in BT549-FOXP3 cells as compared with BT549 or BT549-GFP cells ( Figure 3 ) (BR-1: B75% repression (Po0.0001) and BR-2: B40% repression (P ¼ 0.048), respectively; n ¼ 3 independent experiments). Importantly, when the FOXP3-binding consensus sequences located in BR-1 or BR-2 were mutated, FOXP3-dependent repression of luciferase activity was abolished. In addition, no effect of FOXP3 expression was observed on a control promoter construct (PsiCheck control) in which luciferase transcription was driven by the HSV-TK promoter. Together, these data indicate that FOXP3 is able to directly regulate the SATB1 promoter in BT549 cells.
FOXP3-induced miR expression in BT549 cells
We hypothesized that FOXP3 may act additionally through miRs to downregulate SATB1 in breast epithelial cells. In particular we focused on miR-155 and miR-7 as these miRs have predicted binding sites within the 3 0 -UTR of SATB1. FOXP3-binding regions Feed-forward regulation of SATB1 by FOXP3 N McInnes et al in close proximity to loci encoding miR-155 and two of the three genomic loci encoding miR-7 (miR-7-1 and miR-7-2) have been identified previously . To determine whether FOXP3 can alter the expression of these miRs, the relative levels of miR-7 and miR-155 in BT549 cells expressing pLVEIG-FOXP3 were compared to those in parental BT549 cells by quantitative RT-PCR. Relative to the parental BT549 cell line or GFP-transduced controls, there were significantly elevated levels of miR-7 and miR-155 in the BT549-FOXP3 cells, suggesting that FOXP3 regulates the expression of these miRs in breast epithelial cells (Figure 4 ). Consistent with FOXP3 upregulating the expression of these miRs, we observe higher levels of miR-7 and miR-155 in cultured primary breast epithelia cells human mammary epithelial cells (HMEC) that express endogenous FOXP3 when compared with the parental and control-transduced BT549 cells (Supplementary Figure S5 ).
Downregulation of SATB1 by miR-7 and miR-155
To determine whether miR-7 and miR-155 directly target SATB1 in breast cancer cells, we constructed a luciferase reporter containing the SATB1 3 0 -UTR. The reporter gene was co-transfected into BT549 cells along with pre-miRs for miR-7, miR-155, a combination of both or a non-targeting random sequence control premiR. When tested over a range of concentrations, a significant dose-dependent reduction in the levels of SATB1 3 0 -UTR reporter activity was observed for miR-7 alone (60% reduction, P ¼ 0.03), miR-155 alone (55% reduction, P ¼ 0.03) and the combination of the two miRs (70% reduction, Po0.0001), but not the nontargeting control miR (Figure 5a ). No miR-dependent reduction in the Renilla activity of a control construct lacking the SATB1 3 0 -UTR sequences was observed. Mutations were then introduced to disrupt the miR-7 and miR-155 seed sequences in the SATB1 3 0 -UTR reporter constructs (Figure 1b) . These constructs were co-transfected into BT549 cells with a control miR, premiR-7 or pre-miR-155. Mutation of either of the putative miR-binding sites within the SATB1 3 0 -UTR abolished the ability of the corresponding pre-miR to downregulate Renilla activity, whereas mutation of both miR seed sites prevented the downregulation of Renilla activity by either miR (Figure 5b) . We observed similar miR-7 and miR-155 downregulation of SATB1 3 0 -UTR reporter construct activity in MDA-MB-231 cells, a second breast cancer line known to express high levels of SATB1 (Han et al., 2008) (Supplementary Figure S6) . These observations suggest that the SATB1 3 0 -UTR contains functional binding sites for miR-7 and miR-155, and together the level of these two miRs contribute to the overall level of SATB1 within the cell.
Endogenous miR-7 and miR-155 regulate SATB1 levels in BT549 cells To verify that endogenous miR-7 and miR-155 in BT549 cells can regulate SATB1, we used peptide nucleic acid (PNA) inhibitor molecules against miR-7 or miR-155 to block miR-7 and miR-155 activity, respectively. BT549 cells expressing FOXP3 or GFP were transiently co-transfected with PsiCheck/SATB1 3 0 -UTR reporter constructs and either a control PNA miR inhibitor or specific miR-7 and miR-155 PNA inhibitors. In control GFP cells, co-transfection with PNA inhibitors (100-200 nM) to either miR-7 or miR-155 resulted in a 30-40% increase in reporter activity (n ¼ 3, Po0.001), whereas no significant effect on Renilla activity was observed with the control PNA inhibitor ( Figure 6 ). In BT549 cells expressing FOXP3, a 45% reduction in the SATB1 3 0 -UTR reporter activity relative to BT549 cells expressing GFP alone was apparent in the absence of PNA inhibitors (n ¼ 3, Po0.05), consistent with the FOXP3-dependent increase in the expression of these miRs observed in these cells (Figure 4) . Importantly, co-transfection of these cells with 100-200 nM miR-7 or miR-155 PNA inhibitors caused a dose-dependent, PNA-specific increase (50-60%, Po0.001) in the activity of the SATB1 3 0 -UTR reporter constructs when compared with the BT549 FOXP3 no miR-inhibitor (miR-i) control. No significant effects on reporter activity were observed when FOXP3-expressing cells were co-transfected with control PNA inhibitors. Similar increases in reporter activity were observed when parental BT549 cells were treated with an miR-7 and miR-155 inhibitor, but not a control PNA inhibitor (Supplementary Figure S7) .
Repression of endogenous SATB1 by miR-7 and miR-155
To determine whether miR-7 and miR-155 repress endogenous SATB1, the parental BT549 cells, GFPtransduced BT549 cells and FOXP3-overexpressing BT549 cells were transfected with a control pre-miR, pre-miR-7 or pre-miR-155. Transfection of the parental and GFP lines with either pre-miR-7 or pre-miR-155 caused a significant reduction in the SATB1 mRNA levels as compared with control pre-miR-transduced cells (35-38% reduction (P ¼ 6.35 Â 10 À5 ) and 35-45% reduction (P ¼ 1.4 Â 10 À9 ), respectively) ( Figure 7a ). In FOXP3-transduced cells transfected with control pre-miR, endogenous SATB1 mRNA levels were decreased 45-50% (P ¼ 1.03 Â 10 À12 ) as compared with that in control pre-miR-transfected parental or GFP cell lines. This was most likely due to the combination of the FOXP3-dependent repression of SATB1 transcription and the upregulation of endogenous miR-7 and miR-155 levels within these cells. Importantly, when pre-miR-7 or pre-miR-155 were transfected into FOXP3-expressing cells, a further significant decrease in SATB1 mRNA levels was observed, with a 40-43% Figure 6 miR targeting of SATB1 is blocked by PNA oligos. Transient expression of a PNA inhibitor (miR-i) targeting miR-7 or miR-155 specifically inhibits the miR-mediated repression of the SATB1 3 0 -UTR reporter construct in a dose-dependent manner.
BT549 cells expressing GFP (open bars) show an miR-i-induced increase in SATB1 3
0 -UTR expression when compared with the BT549-GFP no miR-i control (*Po0.001). This is also seen in BT549 cells overexpressing FOXP3 (hatched bars) when compared with the BT549-FOXP3 no miR-i control (**Po0.001). ***Po0.05 compared with the BT549-GFP no miR-i control; n ¼ 3. ) and 70-72% (P ¼ 1.35 Â 10 À8 ) reduction in SATB1 mRNA observed in miR-7 and miR-155 transfected cells, respectively. When compared with the control SATB1 expression levels in BT549 cells, the additive effects of FOXP3 and miR-7 or miR-155 account for a 70-80% reduction in SATB1 expression. These findings were confirmed at the protein level by western blotting (Figure 7b) . To quantitate the effect of FOXP3 and miR-7 and miR-155 on SATB1 protein levels, three independent western blots were analysed and the relative level of SATB1 was normalized to a-tubulin (Figure 7c) . A significant miR-7-and miR-155-dependent reduction in SATB1 protein was observed in all three cell lines. Additionally, FOXP3 expression alone caused a reduction in SATB1 protein levels, with a further reduction in SATB1 levels detected when these cells were also transfected with pre-miR-7 or pre-miR-155. Together, these findings suggest that FOXP3 acts to negatively regulate SATB1 levels both directly, through repression of SATB1 transcription, and indirectly through the induction of miR-7 and miR-155 that then target the 3 0 -UTR of the SATB1 mRNA.
Discussion
The transcription factor FOXP3, a master regulator of Treg cells, has been proposed to function as a tumour suppressor in breast and prostate epithelial cells (Zuo et al., 2007b; Wang et al., 2009) , although the molecular pathways and the targets it regulates are yet to be explored in detail. In Treg cells, FOXP3 orchestrates its transcriptional programme both by directly binding to gene-regulatory regions and also indirectly by controlling other regulators such as transcription factors and miRs Hill et al., 2007; Williams and Rudensky, 2007; Zheng et al., 2007; Sadlon et al., 2010) . In this work, we demonstrate that FOXP3 can also perform its tumour-suppressor function in epithelial cells by direct and indirect mechanisms. Specifically, we show that in breast cancer cell lines SATB1 is repressed by FOXP3 directly, by FOXP3 binding to regulatory regions within the SATB1 gene, and indirectly through the FOXP3 induction of two miRs, miR-7 and miR-155, which themselves target the 3 0 -UTR of SATB1. This suggests that part of FOXP3's tumour-suppressor activity in normal breast may be through the suppression of SATB1 expression. SATB1 has recently been implicated in epithelial-mesenchymal transitions and metastasis in breast cancer. Furthermore, SATB1 protein expression has been linked to poor prognosis in a large cohort of breast cancer patients (Han et al., 2008; Hanker et al., 2010; Kohwi-Shigematsu et al., 2010) . Although there are contradictory reports on the prognostic value of SATB1 expression in breast cancer based on the assessment of transcript levels (Hanker et al., 2010; Iorns et al., 2010) , contamination of SATB1 signals from other cell types such as activated stromal cells or infiltrating T-lymphocytes may explain this (Kohwi-Shigematsu et al., 2010) . Critically, the study by Han et al. (2008) was the only one to score SATB1 protein expression in tumour cells. Importantly, independent studies have also recently linked SATB1 expression to chemotherapy-induced epithelial-to-mesenchymal transitions, metastasis and multidrug resistance within breast cancer (Li et al., 2010a, b) . Three recent studies indicated that high SATB1 mRNA levels correlated with advanced stages of cancer and poor prognosis in breast (Patani et al., 2009) and gastric cancer Lu et al., 2010) . Together, these findings are consistent with SATB1 playing an important role in cancer. Little is known about the regulation of SATB1 and, in particular, the mechanism by which SATB1 expression is induced in breast cancer. We show for the first time that FOXP3 and FOXP3-induced miRs are able to form a feed-forward loop to control SATB1 expression in breast cancer cells. Potentially, the upregulation of FOXP3 or FOXP3-regulated miRs may provide a new therapeutic opportunity for the treatment of breast cancer. As a consequence of FOXP3 being subject to random X-inactivation, only a single allele of FOXP3 needs to be mutated to inactivate FOXP3 function (Liu et al., 2010) . Indeed thus far the majority of mutations and deletions of FOXP3 found in breast cancer samples are heterozygous, with only the FOXP3 allele on the active X-chromosome mutated (Zuo et al., 2007a, b) . This raises the possibility of re-activating the wild-type allele as a potential cancer therapy as demonstrated recently in normal and malignant mammary cells in vitro .
Our findings establish a role for FOXP3 in the suppression of the pro-metastatic oncogene SATB1.
As FOXP3 loss appears to occur more frequently in primary breast cancer cells than does SATB1 induction (Zuo et al., 2007b; Han et al., 2008) , other mechanisms that participate in the suppression of SATB1 such as miR-488 may also need to be lost for SATB1 induction to occur (Li et al., 2010a) . Together, these findings indicate that SATB1 expression is tightly regulated in breast epithelia both through transcriptional control and post-transcriptionally through miRs.
The finding that FOXP3 can regulate miR-7 and miR-155 in breast cancer cell lines suggests that aberrant expression of miRs may be an important consequence of loss of FOXP3 activity in primary tumour cells. The aberrant expression of other miRs in cancer cells has also been linked recently to the loss and/or the oncogenic activation of transcription factors with tumour-suppressor function or oncogenic potential (O'Donnell et al., 2005; Bommer et al., 2007; Reddy et al., 2008; Sander et al., 2008) . The exact role for the FOXP3-induced miRs identified in our study in normal and cancerous epithelial cells is yet to be determined, as each miR can potentially target multiple transcripts (Farazi et al., 2010) . However, experimentally validated miR-7 targets including growth factor receptors and signalling molecules such as EGFR, PAK1, RAF-1, IRS1 and IRS2 are frequently upregulated in cancers (Kefas et al., 2008; Reddy et al., 2008; Pogribny et al., 2010) , supporting a role for miR-7 in FOXP3 tumoursuppressor function. We have also observed the reduced mRNA levels for the miR-7 targets EGFR, PAK1 and RAF-1 in FOXP3-transduced BT549 cells correlating with the increased miR-7 levels (Supplementary Figure S8) , suggesting that, in addition to suppressing SATB1, miR-7 may also suppress other important oncogenes. Although increased miR-7 levels have been associated with aggressiveness in oestrogen receptor-positive (ER þ ) breast cancers (Foekens et al., 2008) , the recent finding that miR-inhibitory effects are generally less potent in ER þ breast cancers provides a possible explanation for this apparent contradiction (Cheng et al., 2009) . Clearly, further work is required to determine the role miR-7 has in breast cancer pathogenesis. Similarly, the role of miR-155 is complex. miR-155 is overexpressed in many cancers, including breast cancer, where it has been shown to promote growth and cell survival (Iorio et al., 2005; Blenkiron et al., 2007; Kong et al., 2010) , which is apparently at odds with its ability to target the SATB1 oncogene as identified in this study, and inconsistent with a role in FOXP3 tumour-suppressor function. These seemingly contradictory findings may reflect the difference between the function of a specific miR in the context of a cancerous cell, compared with a normal cell. In support of this, a recent study indicates that miR-155 overexpression in a murine breast cancer cell line has both tumour-growth-promoting and anti-metastatic effects depending on the stage of cancer development and the site of tumour growth. Importantly, increased miR-155 expression in mouse 4T1 breast tumour cells suppressed the ability of these cells to undergo epithelial-mesenchymal transition and prevented the dissemination of these cells to the lung in metastasis assays in vivo when delivered to the mammary fat pad (Xiang et al., 2011) . In addition, increased miR-155 levels in 4T1 tumour cells were associated with the induction of an epithelial gene expression profile. We propose that within normal breast epithelial cells, FOXP3 maintains the steady-state level of miR-155 required for normal cellular and/or tissue homeostasis, as observed for Treg cells (Kohlhaas et al., 2009; Lu et al., 2009) . However, in the context of multiple changes that occur within a cancerous cell, increased levels of miR-155 may have a deleterious effect.
We propose that re-expression of FOXP3 in cancer cells, in which FOXP3 expression has been lost, will result in the FOXP3-mediated upregulation of miR-155, miR-7 and other miRs, restoring the regulation, which normally occurs in non-malignant cells. In summary, we have identified a feed-forward loop involving FOXP3 and FOXP3-induced miRs, and demonstrated that the oncogene SATB1 is a target for suppression by this loop (Figure 8 ). The identification of other potential targets of FOXP3-dependent feed-forward regulatory loops may provide additional candidates for intervention in breast cancer. 
Materials and methods
Cell lines BT549 cells (ATCC, Manassas, VA, USA) were cultured in RPMI supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. MDA-MB-231 cells (ATCC) and HEK-293T cells (ATCC) were cultured in Dulbecco's modified Eagle's Medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. All cell lines were maintained at 37 1C and 5% CO 2 .
Lentiviral production and transduction
The lentiviral construct pLVEIG-FOXP3 described previously encodes for full-length human FOXP3 transcribed from the Elongation factor-1a promoter, whereas enhanced green fluorescence protein is expressed from an internal ribosome entry site. Lentiviral preparations were generated by transient transfection of HEK-293T cells by using Gag/Pol (7.6 mg); Rev (6.4 mg); VSV-G (3.6 mg) and a transfer vector containing the gene of interest (12.4 mg) as described previously (Barry et al., 2001) . Breast cancer cell lines were transduced with lentivirus at a multiplicity of infection of 2 and sorted for GFP on day 4. The sorted cells were cultured and used for further experiments.
Cell proliferation assay
The proliferative capacity of cells was measured by using the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit as per the manufacturer's recommendations (Promega, Madison, WI, USA). FOXP3-transduced and control cell lines were tested in triplicate over a 5-day period. Following the addition of the CellTiter 96 AQueous One Solution Reagent, plates were incubated at 37 1C in a humidified 5% CO 2 incubator for 1 h, prior to measuring absorbance at 490 nm.
Quantitative real-time PCR Total RNA was extracted from cell lines by using the miRNeasy kit (Qiagen, Hilden, Germany) and converted to cDNA by using the Quantitect Reverse Transcription kit (Qiagen). Semiquantitative RT-PCR was performed by using the KAPA SYBR Fast Universal quantitative PCR kit (KAPA Biosystems, Cambridge, MA, USA) in triplicate. PCRs were performed on a Corbett real-time PCR machine (Rotor-Gene 6000). Results from three independent experiments were analysed by using the Rotor-Gene 6000 software and normalized to expression of the reference transcript Ribosomal Protein L13a (RPL13a). The primers used are listed in Supplementary Table S1 .
miR RT-PCR Target-specific reverse transcription was performed by using the Taqman miR Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) and Taqman miR assay probes (Applied Biosystems; . Detection of mature miR was performed in triplicate using specific Taqman miR assays (Applied Biosystems). The assays were run on a Corbett Real-time machine (Rotor-Gene 6000), with miR-24 used as a reference for normalization. Results from three independent assays were analysed by using the Rotor-Gene 6000 software.
Western blotting and immunodetection
Total cell lysate was extracted from cells using radio-immunoprecipitation assay buffer (1% NP-40, 0.1%. sodium dodecyl sulphate, 0.1% Na deoxycholate, 100 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 50 mM Hepes (pH 7.4), 1 mM Pefablock, 1 Â complete protease inhibitor cocktail). Protein estimation was performed by using a Dc assay kit (Bio-Rad, Hercules, CA, USA). Western blots were performed with total protein (30 mg) as per the BD Biosciences protocol. Nitrocellulose membranes were probed with a mouse anti-SATB1 monoclonal antibody (BD Biosciences, Franklin Lakes, NJ, USA; clone 14/SATB1). Proteins were detected with a West Dura Chemiluminescent detection kit (Pierce, Thermo Fisher Scientific, Rockford, IL, USA). Band intensities were quantitated by using ImageJ 1.43 (http://rsbweb.nih.gov/ij/) after scanning on a G: BOX iChemi imager (Syngene, Cambridge UK). As a loading control, filters were stripped as per instructions for the Western Blot Stripping Solution (Alpha Diagnostics International, San Antonio, TX, USA) and re-probed with a polyclonal rabbit anti-a-tubulin antibody (Rockland Immunochemicals, Gilbertsville, PA, USA).
Luciferase constructs and assays
Promoter reporter vectors were constructed to determine the FOXP3 responsiveness of the FOXP3-binding regions in the human SATB1 gene. FOXP3-binding regions were cloned into the pGL4.24 vector downstream from a minP element and upstream from a destabilized firefly luciferase. To measure the response to FOXP3, SATB1 promoter reporter constructs were transfected into parental, FOXP3-expressing or GFP lines together with pGL4.74 Renilla luciferase construct using Lipofectamine 2000. Luciferase activity was assessed 24 h after transfection using a Dual Luciferase kit (Promega) as per the manufacturer's instructions in a Veritas luminescent plate reader (Promega).
To determine the effect of miRs on SATB1 expression and to identify functional miR-binding sites in the 3 0 -UTR of SATB1, the 3 0 -UTR was amplified by PCR and cloned into the psiCHECK-2 vector (Promega). Mutations in putative miRbinding sites were made by using the KAPA HiFi HotStart mutagenesis PCR protocol (KAPA Biosystems, Boston, MA, USA). HEK-293T cells or breast cancer cell lines were then transfected with psiCHECK-2 constructs and synthetic pre-miR molecules (Ambion, Austin, TX, USA) by using Hiperfect transfection reagent (Qiagen). Transfections were performed in triplicate and luciferase activity was measured 24 h later. To determine the effect of pre-miR overexpression on endogenous SATB1 levels, breast cancer cell lines (BT549 and MDA-MB-231) were transfected with pre-miR molecules by using the Hiperfect transfection reagent and RNA or protein was isolated as described above 24 h or 48 h after transfection, respectively. miR knockdown PNA miR inhibitors for miR-7 and miR-155, and a control non-targeting PNA, were purchased from Panagene (Daejeon, Korea). To measure knockdown of miRs in luciferase reporter assays, BT549 cell lines were transfected with reporter plasmids and the PNA inhibitors using Lipofectamine 2000 in a 96-well format and luciferase activity was determined 24 h later.
